EYP001 is a synthetic FXR agonist developed by ENYO Pharma and currently in Phase II trial for hepatitis B virus (HBV) infection as well as for NASH treatment. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.